Print this page


  1. Cancer survival in Australia, Canada, Denmark, Norway, Sweden and the UK, 1995-2007: the International Cancer Benchmarking Partnership, 2011, The Lancet,, accessed 9 June 2014

    The International Cancer Benchmarking Partnership (ICBP) includes data from population-based cancer registries in 12 jurisdictions in six countries. Data was provided for 2.4 million adults diagnosed with primary colorectal, lung, breast (women), or ovarian cancer during 1995 - 2007, with follow-up to 31 December 2007. One-year and five-year relative survival estimates were calculated.
  2. EUROCARE-5-a population-based study of cancer survival in Europe 1999-2007 by country and age,, EUROCARE, accessed 9 June 2014

    The EUROCARE project provides the largest European population-based dataset for comparison of cancer survival. EUROCARE-5 provides the most up-to-date survival analysis for patients diagnosed with cancer in 2000-2007 from 107 population-based cancer registries across 29 European countries.
  3. 2018 Global progress report on implementation of the WHO Framework Convention on Tobacco Control. Geneva: World Health Organization; 2018. accessed 10 December 2018

    This source includes data on the implementation of a national tobacco control strategy, plan or programme in accordance with the WHO FCTC. The WHO FCTC requires each Party (country) to submit periodic reports on its implementation of the Convention to the Conference of Parties.

    The data extracted was from the global progress reports from January to March 2018; part of the Convention requires Parties to implement a national tobacco control plan. Parties are required to respond to the following question: have you adopted and implemented comprehensive multisectoral national tobacco control strategies, plans and programmes in accordance with the Convention?
  4. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Bray, F. , Ferlay, J. , Soerjomataram, I. , Siegel, R. L., Torre, L. A. and Jemal, A. (2018), CA: A Cancer Journal for Clinicians, 68: 394-424. doi:10.3322/caac.21492

    The GLOBOCAN data provides contemporary estimates of the incidence, mortality and prevalence from major types of cancer, at national level, for 185 countries of the world. The estimates are based on the most recent data available at the International Agency for Research on Cancer (IARC) and on information publicly available on the internet, but more recent figures may be available directly from local sources.

    The methods of estimation are country-specific and the quality of the estimation depends upon the quality and on the amount of the information available for each country. The GLOBOCAN database goes into extensive detail about the methods of calculation - for more information please use the link above.
  5. National Data

    GLCC members were asked to validate the data for their country and identify any more recent national data. If more recent data were found then the source reference has been recorded as national data. If you would like more information about this data then please contact who will be able to provide you with more information. The following national data is included in the e-Atlas:
  6. Noncommunicable Diseases Country Profiles 2014, World Health Organization (WHO), accessed 10 December 2018

    This source provides individual country profiles on the capacity to address and respond to noncommunicable diseases (NCD). The data was collected from responses to the WHO NCD country capacity survey (CSS), which was conducted in 2010-2013. From the 193 countries, defined as WHO Member States, 178 countries responded.

    To assess a country's capacity to address and respond to NCD, the CSS included the following yes/no questions:
    • Existence of a cancer plan - has an integrated or topic-specific policy / programme / action plan which is currently operational for cancer?
    • Existence of a cancer registry - has a national, population-based cancer registry?
  7. Global surveillance of cancer survival 1995-2009: analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2), Claudia Allemani, Hannah K Weir, Helena Carreira, Rhea Harewood, Devon Spika, Xiao-Si Wang, et al., and the CONCORD Working Group. The Lancet, published on-line 26 November 2014, accessed 8 December 2014

    CONCORD-2 includes analysis of global variation and trends in survival for 10 cancers in adults, and childhood leukaemia, and trends in survival from 1995 to 2009. It includes data on over 25 million cancer patients, provided by 279 population-based cancer registries in 67 countries. More than 2,500 data sets were checked and analysed. Net survival estimates up to five years after diagnosis were published for 9 countries in Africa, 8 in Central and South America, 2 in North America, 16 in Asia, 30 in Europe, and 2 in Oceania; 40 countries contributed data with 100% coverage of the national population. For more information please visit:
  8. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37,513,025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. DOI:

    CONCORD-3 updates the world-wide surveillance of cancer survival to 2014. It includes 18 cancers and groups of cancer that collectively represent 75% of the global cancer burden.

    CONCORD-3 includes individual records for 37.5 million patients diagnosed with cancer during the 15-year period 2000-14. Data were provided by 322 population-based cancer registries in 71 countries and territories, 47 of which provided data with 100% population coverage. The study includes 18 cancers or groups of cancers: oesophagus, stomach, colon, rectum, liver, pancreas, lung, breast (women), cervix, ovary, prostate, and melanoma of the skin in adults, and brain tumours, leukaemias, and lymphomas in both adults and children. For more information, please visit:

    CONCORD-3 flags (§) survival figures that may be less reliable for international comparison, to help interpretation. They do this when they have to exclude more patients than expected from the survival analyses, usually because their date of diagnosis or death was not accurately known, or because some deaths may not have been recorded.